All In Biotech

Drug Trial Radar · NCT06093672

Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera

Randomized, Open-label, Multicenter Phase 3 Study to Assess the Efficacy and Safety of GIVinostat Versus Hydroxyurea IN JAK2V617F-positive High-risk Polycythemia Vera Patients: the GIV-IN PV TRIAL

Last checked: Nov 19, 2026Latest source record: Mar 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 220 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

220

Planned (sponsor's estimate)

Start

Mar 26, 2024

Primary completion

Jul 2026

Study completion Jul 2026

Sponsor

Lead sponsor
ItalfarmacoIndustry
Sponsor type
Industry
Collaborators
PPD Development, LP
First posted
Oct 23, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to compare the efficacy and safety of givinostat to hydroxyurea in Jak2V617F-positive high risk polycythemia vera patients.

Conditions

  • Polycythemia Vera

Interventions

  • GivinostatDrug

    Oral. The dosage must be modified, according to the manifestation of toxicities or lack of efficacy, with the aim to achieve an optimized dose.

  • HydroxyureaDrug

    Oral. The dosage must be modified, according to the manifestation of toxicities or lack of efficacy, with the aim to achieve an optimized dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients achieving a response at Week 48.Time frame: week 25 - week 48

Locations

90 sites in 16 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama · Not yet recruiting

  • Emad Ibrahim, MD, Inc

    Redlands, California · Recruiting

  • US Oncology Inc

    Englewood, Colorado · Recruiting

  • American Oncology Partners of Maryland, PA

    Bethesda, Maryland · Recruiting

  • Icahn School of Medicine at Mount Sinai

    New York, New York · Recruiting

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina · Recruiting

  • The Cleveland Clinic Foundation

    Cleveland, Ohio · Recruiting

  • Oncology Associates of Oregon, P.C.

    Eugene, Oregon · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Texas Oncology (Webster) - USOR

    Houston, Texas · Recruiting

  • Texas Oncology-Denison Cancer Center

    Sherman, Texas · Recruiting

  • University of Utah - Huntsman Cancer Institute - PPDS

    Salt Lake City, Utah · Recruiting

  • The James Cancer Hospital and Solove Research Institute

    Roanoke, Virginia · Recruiting

  • VA Puget Sound Health Care System - NAVREF - PPDS

    Seattle, Washington · Recruiting

  • Landesklinikum Wiener Neustadt

    Wiener Neustadt, Lower Austria, Austria · Recruiting

  • Medizinische Universitat Wien (Medical University of Vienna)

    Vienna, State of Vienna, Austria · Recruiting

  • Ordensklinikum Linz GmbH Elisabethinen

    Linz, Upper Austria, Austria · Recruiting

  • Klinikum Wels-Grieskirchen GmbH

    Wels, Upper Austria, Austria · Recruiting

  • University Multiprofile Hospital for Active Treatment Sveti Georgi EAD

    Plovdiv, Bulgaria · Recruiting

  • University Multiprofile Hospital for Active Treatment - Prof. Dr. Stoyan Kirkovich AD

    Stara Zagora, Bulgaria · Recruiting

  • Acibadem City Clinic Multiprofile Hospital for Active Treatment Tokuda

    Sofia, Sofia-Grad, Bulgaria · Recruiting

  • Clinical Hospital Center Rijeka - PPDS

    Rijeka, Croatia · Recruiting

  • Clinical Hospital Center Rijeka

    Rijeka, Croatia · Not yet recruiting

  • General Hospital Sibenik

    Šibenik, Croatia · Not yet recruiting

  • Clinical Hospital Dubrava

    Zagreb, City of Zagreb, Croatia · Recruiting

  • Hôpital Saint Louis

    Paris, France · Recruiting

  • Centre Hospitalier de Saint-Quentin

    Saint-Quentin, Aisne, France · Recruiting

  • CHU de Nice

    Nice, Alpes-Maritimes, France · Recruiting

  • Centre Hospitalier de Troyes

    Troyes, Aube, France · Recruiting

  • Hopital d'Argenteuil

    Argenteuil, Île-de-France Region, France · Recruiting

  • Hôpital Bretonneau

    Tours, Indre-et-Loire, France · Recruiting

  • CHU Nantes

    Nantes, Loire-Atlantique, France · Recruiting

  • CHU Angers

    Angers, Maine-et-Loire, France · Recruiting

  • CHU Amiens Hôpital Sud

    Amiens, Somme, France · Recruiting

  • OncoResearch Lerchenfeld GmbH

    Hamburg, Germany · Recruiting

  • Medizinische Fakultät Mannheim der Universität Heidelberg, Universitätsmedizin Mannheim

    Mannheim, Baden-Wurttemberg, Germany · Recruiting

  • Gemeinschaftspraxis Hämatologie - Onkologie

    Dresden, Saxony, Germany · Recruiting

  • Universitätsmedizin Halle, Universitätsklinikum Halle, Klinik für Innere Medizin IV

    Halle, Saxony-Anhalt, Germany · Withdrawn

  • Gyor-Moson-Sopron Vármegyei Petz Aladár Egyetemi Oktató Kórház

    Győr, Győr-Moson-Sopron, Hungary · Recruiting

  • Szabolcs-Szatmár-Bereg Vármegyei Oktatókórház

    Nyíregyháza, Szabolcs-Szatmár-Bereg, Hungary · Recruiting

Showing 40 of 90 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.